Clinical Trial Update: The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating dendritic cell/tumor fusion vaccines as a novel immunotherapy for multiple myeloma has completed the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Dendritic cell/tumor fusion vaccine

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED